doi:10.16150/j.1671-2870.2019.06.005

Abstract

CLC Number:

R733.4

References 21

[1]	Dang CV. MYC on the path to cancer[J]. Cell, 2012, 149(1):22-35. doi: 10.1016/j.cell.2012.03.003 pmid: 22464321
[2]	López C, Kleinheinz K, Aukema SM, et al. Genomic and transcriptomic changes complement each other in the pathogenesis of sporadic Burkitt lymphoma[J]. Nat Commun, 2019, 10(1):1459. doi: 10.1038/s41467-019-08578-3 URL
[3]	Doose G, Haake A, Bernhart SH, et al. MINCR is a MYC-induced lncRNA able to modulate MYC's transcriptional network in Burkitt lymphoma cells[J]. Proc Natl Acad Sci U S A, 2015, 112(38):E5261-5270.
[4]	Poole CJ, Zheng W, Lee H, et al. Targeting the MYC Oncogene in Burkitt Lymphoma through HSP90 inhibition[J]. Cancers, 2018, 10(11):pii448.
[5]	Egle A, Harris AW, Bouillet P, et al. Bim is a suppressor of Myc-induced mouse B cell leukemia[J]. Proc Natl Acad Sci U S A, 2004, 101(16):6164-6169. doi: 10.1073/pnas.0401471101 URL
[6]	Frenzel A, Labi V, Chmelewskij W, et al. Suppression of B-cell lymphomagenesis by the BH3-only proteins Bmf and Bad[J]. Blood, 2010, 115(5):995-1005. doi: 10.1182/blood-2009-03-212670 pmid: 19965635
[7]	Michalak EM, Jansen ES, Happo L, et al. Puma and to a lesser extent Noxa are suppressors of Myc-induced lymphomagenesis[J]. Cell Death Differ, 2009, 16(5):684-696. doi: 10.1038/cdd.2008.195 pmid: 19148184
[8]	Hrckulak D, Kolar M, Strnad H, et al. TCF/LEF transcription factors: An update from the internet resources[J]. Cancers, 2016, 8(7) pii: E70.
[9]	Kee BL. E and ID proteins branch out[J]. Nat Rev Immunol, 2009, 9(3):175-184. doi: 10.1038/nri2507 URL
[10]	Schmitz R, Young RM, Ceribelli M, et al. Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics[J]. Nature, 2012, 490(7418):116-120. doi: 10.1038/nature11378 URL
[11]	Cato MH, Chintalapati SK, Yau IW, et al. Cyclin D3 is selectively required for proliferative expansion of germinal center B cells[J]. Mol Cell Biol, 2011, 31(1):127-137. doi: 10.1128/MCB.00650-10 URL
[12]	Peled JU, Yu JJ, Venkatesh J, et al. Requirement for cyclin D3 in germinal center formation and function[J]. Cell Res, 2010, 20(6):631-646. doi: 10.1038/cr.2010.55 URL
[13]	Schmitz R, Ceribelli M, Pittaluga S, et al. Oncogenic mechanisms in Burkitt lymphoma[J]. Cold Spring Harb Perspect Med, 2014, 4(2)pii: a014282.
[14]	Diehl JA, Cheng M, Roussel MF, et al. Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization[J]. Genes Dev, 1998, 12(22):3499-3511. doi: 10.1101/gad.12.22.3499 URL
[15]	Preudhomme C, Dervite I, Wattel E, et al. Clinical significance of p53 mutations in newly diagnosed Burkitt's lymphoma and acute lymphoblastic leukemia: a report of 48 cases[J]. J Clin Oncol, 1995, 13(4):812-820. pmid: 7707106
[16]	Hüllein J, Slabicki M, Rosolowski M, et al. MDM4 is targeted by 1q gain and drives disease in Burkitt lymphoma[J]. Cancer Res, 2019, 79(12):3125-3138.
[17]	Farhat M, Poissonnier A, Hamze A, et al. Reversion of apoptotic resistance of TP53-mutated Burkitt lymphoma B-cells to spindle poisons by exogenous activation of JNK and p38 MAP kinases[J]. Cell Death Dis, 2014, 5:e1201.
[18]	Lee JH, Park SJ, Hariharasudhan G, et al. ID3 regulates the MDC1-mediated DNA damage response in order to maintain genome stability[J]. Nat Commun, 2017, 8(1):903. doi: 10.1038/s41467-017-01051-z URL
[19]	Love C, Sun Z, Jima D, et al. The genetic landscape of mutations in Burkitt lymphoma[J]. Nat Genet, 2012, 44(12):1321-1325. doi: 10.1038/ng.2468 URL
[20]	Helming KC, Wang X, Wilson BG, et al. ARID1B is a specific vulnerability in ARID1A-mutant cancers[J]. Nat Med, 2014, 20(3):251-254.
[21]	Shen J, Peng Y, Wei L, et al. ARID1A deficiency impairs the DNA damage checkpoint and sensitizes cells to PARP Inhibitors[J]. Cancer Discov, 2015, 5(7):752-767. doi: 10.1158/2159-8290.CD-14-0849 URL

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References 21

Related Articles 10

Recommended Articles

Metrics

Comments

[1]	FENG Guowei, ZHANG Xiaojuan, GUO Rui, GUAN Zhe, WANG Yue. The prognostic value of pretreatment ¹⁸F-FDG PET/CT in extranodal natural killer/T-cell lymphoma [J]. Journal of Diagnostics Concepts & Practice, 2021, 20(06): 533-539.
[2]	YUE Jingjing, SONG Qi, JIANG Xufeng, WANG Li, ZHAO Weili, YAN Fuhua. Comparison of magnetic resonance whole body diffusion weighted imaging with FS-T2WI and FDG-PET/CT for initial staging and detection of lesion in newly diagnosed lymphoma [J]. Journal of Diagnostics Concepts & Practice, 2021, 20(06): 540-546.
[3]	MENG Leijun, ZHANG Jing, WANG Xueli, LI Zhi, ZHANG Hong, ZENG Naiyan. Identification of differentially expressed target genes in pediatric Burkitt lymphoma and its clinical application [J]. Journal of Diagnostics Concepts & Practice, 2020, 19(03): 248-257.
[4]	MA Yuanyuan, WANG Yan, SONG Qi, CHENG Kemin, ZHAO Xia, WANG Li, JIANG Xufeng, ZHAO Weili, YAN Fuhua. Analysis of CT imaging characteristics of primary pulmonary lymphoma and review of literature [J]. Journal of Diagnostics Concepts & Practice, 2018, 17(05): 533-537.
[5]	. [J]. Journal of Diagnostics Concepts & Practice, 2018, 17(05): 512-520.
[6]	. [J]. Journal of Diagnostics Concepts & Practice, 2017, 16(05): 557-560.
[7]	. [J]. Journal of Diagnostics Concepts & Practice, 2017, 16(05): 460-463.
[8]	. [J]. Journal of Diagnostics Concepts & Practice, 2017, 16(04): 437-441.
[9]	. [J]. Journal of Diagnostics Concepts & Practice, 2017, 16(04): 432-433.
[10]	LI Jiaming, ZHANG Sujiang, WANG Ying, YAN Zeying, LIU Zhiyin, SUN Haimin, CHEN Yubao, CHEN Yu, LUO Fangxiu, SUN Jing. Chronic myelomonocytic leukemia accompanied with extranodal lymphoma : a clinical feature analysis [J]. Journal of Diagnostics Concepts & Practice, 2018, 17(01): 76-81.